A Swedish cohort study shows 13% (95% CI, 2-22%) lower risk of kidney function decline or kidney failure and 12% (95% CI, 3-20%) lower risk of acute kidney injury with use of direct oral anticoagulants vs. vitamin K antagonists for non-valvular atrial fibrillation.
The relative safety of anticoagulation with direct oral anticoagulants (DOAC) or vitamin K antagonists (VKA) remains inconclusive, particularly with regards to kidney outcomes.
In a cohort of patients with non-valvular atrial fibrillation from Sweden, researchers observed that compared with VKA, DOAC initiation was associated with a lower risk of the composite of kidney failure and sustained 30% eGFR decline, as well as a lower risk of AKI occurrence.
In agreement with trial evidence, DOAC vs VKA treatment was associated with a lower risk of major bleeding, but a similar risk of the composite of stroke, systemic embolism, or death.
Source: Read Full Article